BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology DevelopmentBusiness Wire • 01/06/26
These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.Barrons • 01/02/26
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026Proactive Investors • 12/24/25
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)Zacks Investment Research • 12/23/25
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer UseZacks Investment Research • 12/22/25
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trialReuters • 12/22/25
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancerBusiness Wire • 12/15/25
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025Accesswire • 12/08/25
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailingProactive Investors • 12/08/25
Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer EngagementBusiness Wire • 12/04/25
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASHBusiness Wire • 12/04/25
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled HypertensionZacks Investment Research • 12/03/25
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertensionBusiness Wire • 12/02/25